Koninklijke Philips (PHG)
(Delayed Data from NYSE)
$21.07 USD
+0.35 (1.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.08 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Royal Philips (PHG) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.85 | $25.00 | $18.70 | 5.45% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Royal Philips comes to $21.85. The forecasts range from a low of $18.70 to a high of $25.00. The average price target represents an increase of 5.45% from the last closing price of $20.72.
Analyst Price Targets (2 )
Broker Rating
Royal Philips currently has an average brokerage recommendation (ABR) of 3.71 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 3.71 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, one is Strong Buy, representing 14.29% of all recommendations. A month ago, Strong Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 3 | 3 | 3 | 3 | 2 |
ABR | 3.71 | 3.71 | 3.71 | 3.71 | 3.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/7/2024 | Exane BNP Paribas | Hugo Solvet | Not Available | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.71 |
ABR (Last week) | 3.71 |
# of Recs in ABR | 7 |
Average Target Price | $21.85 |
LT Growth Rate | 12.60% |
Industry | Medical - Products |
Industry Rank by ABR | 142 of 252 |
Current Quarter EPS Est: | NA |